Chorea News and Research

RSS

Valbenazine improves chorea associated with Huntington's disease

The drug valbenazine statistically improves chorea, a movement disorder commonly associated with Huntington's disease, when compared to a placebo, according to a recent international study led by UTHealth Houston researcher Erin Furr Stimming, MD, who served as principal investigator on behalf of the KINECT-HD Huntington Study Group.

19 May 2023

New drug shows promise in treating a movement disorder associated with Huntington's disease

A new drug has proven beneficial in treating a movement disorder commonly associated with Huntington's disease, according to a recent international study led by UTHealth Houston researcher Erin Furr Stimming, MD, who served as principal investigator on behalf of the KINECT-HD Huntington Study Group.

13 Apr 2022

COVID-19 and subacute neuropsychiatric symptoms in adolescents

A new paper discusses neurologic symptoms in children with COVID-19.

27 Oct 2021

New mouse line reveals the state of protein balance in the mammalian brain for the first time

Proteins are the "tools" of our cells – they are essential to all vital tasks. However, they are only able to do their jobs if they fold correctly and adopt their respective, very specific 3D structure.

20 Aug 2021

Autophagy disruption may be at the root of early cognitive changes in Huntington’s disease

Huntington's Disease (HD) is a progressive neurodegenerative condition characterized by motor, cognitive, and psychiatric symptoms, and motor symptoms are often preceded by cognitive changes.

15 Jul 2021

About 4 in 100 COVID-19 hospitalized children may develop neurological complications, a study finds

In a recently published article in The Lancet’s Child & Adolescent Health, scientists have described in detail neurological and psychiatric manifestations of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in children. As mentioned in the study, an estimated prevalence of infection-related neurological complications and pediatric inflammatory multisystem syndrome in hospitalized children and adolescents is about 3.8 cases per 100 patients.

15 Jul 2021

Mass spectrometry: An important tool to unravel mechanisms underlying Huntington's disease

Mass spectrometry has emerged as an important analytical tool for gaining a better understanding of mechanisms underlying Huntington's disease (HD), alongside the increased availability of cell and animal models of the disease.

14 Jul 2021

Huntington’s disease mutant gene affects brain and body growth in childhood

There is growing evidence to support the hypothesis that there is a neurodevelopmental component to the late-onset neurodegeneration occurring in the brain of huntingtin gene (HTT gene) mutation carriers, and that this increased susceptibility to brain cell death begins during childhood.

6 Jan 2021

Novel brain pathology could improve diagnosis, treatment of neurodegenerative diseases

Bristol scientists have discovered a novel pathology that occurs in several human neurodegenerative diseases, including Huntington's disease.

30 Jun 2020

SAFB1 may be a diagnostic marker for neurodegenerative diseases, shows study

Bristol scientists have discovered a novel pathology that occurs in several human neurodegenerative diseases, including Huntington's disease.

30 Jun 2020

AFFiRiS AG announces results of phase 1 trial with PD01A in Parkinson's

AFFiRiS AG, a clinical-stage biotechnology company developing novel disease-modifying specific active immunotherapies (SAITs), today announced that detailed results of the phase 1 clinical program with its lead candidate PD01 in early Parkinson's disease (PD) patients were published in the peer-reviewed journal The Lancet Neurology.

18 Jun 2020

AFFiRiS announces preclinical results of monoclonal antibody mAB C6-17 in Huntington's

AFFiRiS, a clinical-stage biotechnology company developing novel disease-modifying specific active immunotherapies, today announced that detailed preclinical results with its monoclonal antibody mAB C6-17 to treat Huntington's Disease were published in the peer-reviewed journal Neurobiology of Disease.

3 Jun 2020

Gene therapy regenerates functional new neurons in mouse models of HD

Huntington's disease (HD) is a rare disease characterized by abnormal chorea movement and caused by Huntingtin (Htt) gene mutation and neurodegeneration in a brain area called striatum.

28 Feb 2020

Scientists evaluate mouse models used for developing new treatments for Huntington's disease

Huntington's disease (HD) is an incurable and fatal hereditary disease. Developing disease-modifying drugs to treat patients with HD depends on studying them in animal models. Scientists evaluated the mouse models used for developing new treatments for mood disorders in HD and recommended which of these models are most relevant to their studies.

11 Dec 2019

Huntington's disease patients need to better understand the risks and benefits of new therapies

For patients with Huntington's disease (HD), clinical trials can offer hope when there are no treatments available despite unknowns about whether the therapy will work or is safe.

10 Dec 2019

Q-Suite Motor Assessment Tool helps detect subtle motor abnormalities in children

In clinical trials of adults with Huntington's disease (HD) the Q-Suite Motor Assessment Tool (Q-Motor) has proven to be helpful to detect and quantitate subtle motor abnormalities.

22 Oct 2019

Pluripotent stem cells help advance understanding of how Huntington's disease develops

Huntington's disease (HD) is a fatal hereditary disease for which there is no cure. A novel study from Cedars-Sinai Medical Center, Los Angeles, using pluripotent stem cells advances understanding of how the disease develops and may help pave the way for identifying pathways for future treatments.

21 Oct 2019